A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and Acceptable Tolerability in Advanced RCC
Findings from the COSMIC-021 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
People with Intellectual Disability at Increased Risk of Cancer
Findings from a population-based cohort study
Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
The results of the KEYNOTE-122 study
Contribution of the US NCI Clinical Studies Groups to Substantial Gains in Life Years Among Patients with Cancer
Critical role of government-sponsored cancer research
Automated Detection of Microsatellite Status in Early Colon Cancer by Infrared Imaging Combined with Artificial Intelligence
Findings from samples of the AIO ColoPredictPlus 2.0 registry study
Copanlisib Combined with Rituximab Shows Superior Efficacy over Placebo and Rituximab in Relapsed Marginal Zone Lymphoma
PI3K inhibitor, copanlisib investigated in a phase III, CHRONOS-3 study
FDA Grants Accelerated Approval to Zanubrutinib for Marginal Zone Lymphoma
Approval is based on the results from the BGB-3111-214 and BGB-3111-AU-003 studies
Deep Learning Model Applied to Digital Pathology Slides Could Predict the Risk of Relapse in Invasive Breast Cancer
Development of novel model for prediction of distant relapse in patients with early breast cancer
Organ-Sparing Potentials from the Neoadjuvant Pembrolizumab Treatment in Patients with dMMR/MSI-H Solid Tumours
Findings from a phase II open-label study in patients with localised solid tumours
Safety and Antitumour Activity of a First-in-Class, Oral, Selective CDK7 Inhibitor
Findings from a first-in-human, modular study with samuraciclib (CT7001)
Trastuzumab Deruxtecan Demonstrates Robust and Durable Activity in Previously Treated Metastatic NSCLC with HER2 mutations
The results from the DESTINY-Lung01 study
The Use of Geriatric Assessment Tools to Tailor the Treatment in Elderly Patients with Locally Advanced Head and Neck Cancer
The results of the ELDERLY study